Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet Copehagen University Hospital, Copenhagen, Denmark.
Department of Clinical Medicine, Faculty of Health, Univeristy of Copenhagen (UCPH), Copenhagen, Denmark; School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom.
Semin Nucl Med. 2022 Nov;52(6):781-796. doi: 10.1053/j.semnuclmed.2022.05.002. Epub 2022 Jun 22.
PET/CT with the tracer 2-[F]fluoro-2-deoxy-D-glucose ([F]FDG) has improved diagnostic imaging in cancer and is routinely used for diagnosing, staging and treatment planning in lung cancer patients. However, pitfalls of [F]FDG-PET/CT limit the use in specific settings. Additionally, lung cancer is still the leading cause of cancer associated death and has high risk of recurrence after curative treatment. These circumstances have led to the continuous search for more sensitive and specific PET tracers to optimize lung cancer diagnosis, staging, treatment planning and evaluation. The objective of this review is to present and discuss current knowledge and perspectives of new PET tracers for use in lung cancer. A literature search was performed on PubMed and clinicaltrials.gov, limited to the past decade, excluding case reports, preclinical studies and studies on established tracers such as [F]FDG and DOTATE. The most relevant papers from the search were evaluated. Several tracers have been developed targeting specific tumor characteristics and hallmarks of cancer. A small number of tracers have been studied extensively and evaluated head-to-head with [F]FDG-PET/CT, whereas others need further investigation and validation in larger clinical trials. At this moment, none of the tracers can replace [F]FDG-PET/CT. However, they might serve as supplementary imaging methods to provide more knowledge about biological tumor characteristics and visualize intra- and inter-tumoral heterogeneity.
正电子发射断层扫描/计算机断层扫描（PET/CT）结合示踪剂 2-[F]氟代-2-脱氧-D-葡萄糖（[F]FDG）提高了癌症的诊断成像能力，并且常用于肺癌患者的诊断、分期和治疗计划。然而，[F]FDG-PET/CT 的局限性限制了其在特定情况下的使用。此外，肺癌仍然是癌症相关死亡的主要原因，并且在根治性治疗后具有高复发风险。这些情况导致人们不断寻找更敏感和更特异的 PET 示踪剂，以优化肺癌的诊断、分期、治疗计划和评估。本综述的目的是介绍和讨论用于肺癌的新型 PET 示踪剂的现有知识和观点。在 PubMed 和 clinicaltrials.gov 上进行了文献检索，仅限于过去十年，排除病例报告、临床前研究和对已建立的示踪剂（如[F]FDG 和 DOTATE）的研究。评估了检索到的最相关的论文。已经开发了几种针对特定肿瘤特征和癌症标志的示踪剂。少数示踪剂已经得到了广泛的研究，并与[F]FDG-PET/CT 进行了头对头比较，而其他示踪剂则需要在更大的临床试验中进行进一步的研究和验证。目前，还没有一种示踪剂可以替代[F]FDG-PET/CT。然而，它们可以作为补充成像方法，提供更多关于肿瘤生物学特征的知识，并可视化肿瘤内和肿瘤间的异质性。
